1870 related articles for article (PubMed ID: 34379915)
1. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
Ali K; Berman G; Zhou H; Deng W; Faughnan V; Coronado-Voges M; Ding B; Dooley J; Girard B; Hillebrand W; Pajon R; Miller JM; Leav B; McPhee R
N Engl J Med; 2021 Dec; 385(24):2241-2251. PubMed ID: 34379915
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
Creech CB; Anderson E; Berthaud V; Yildirim I; Atz AM; Melendez Baez I; Finkelstein D; Pickrell P; Kirstein J; Yut C; Blair R; Clifford RA; Dunn M; Campbell JD; Montefiori DC; Tomassini JE; Zhao X; Deng W; Zhou H; Ramirez Schrempp D; Hautzinger K; Girard B; Slobod K; McPhee R; Pajon R; Das R; Miller JM; Schnyder Ghamloush S;
N Engl J Med; 2022 May; 386(21):2011-2023. PubMed ID: 35544369
[TBL] [Abstract][Full Text] [Related]
3. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Frenck RW; Klein NP; Kitchin N; Gurtman A; Absalon J; Lockhart S; Perez JL; Walter EB; Senders S; Bailey R; Swanson KA; Ma H; Xu X; Koury K; Kalina WV; Cooper D; Jennings T; Brandon DM; Thomas SJ; Türeci Ö; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
N Engl J Med; 2021 Jul; 385(3):239-250. PubMed ID: 34043894
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
Anderson EJ; Creech CB; Berthaud V; Piramzadian A; Johnson KA; Zervos M; Garner F; Griffin C; Palanpurwala K; Turner M; Gerber J; Bennett RL; Ali K; Ampajwala M; Berman G; Nayak J; Chronis C; Rizzardi B; Muller WJ; Smith CA; Fuchs G; Hsia D; Tomassini JE; DeLucia D; Reuter C; Kuter B; Zhao X; Deng W; Zhou H; Ramirez Schrempp D; Hautzinger K; Girard B; Slobod K; McPhee R; Pajon R; Aunins A; Das R; Miller JM; Schnyder Ghamloush S;
N Engl J Med; 2022 Nov; 387(18):1673-1687. PubMed ID: 36260859
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
El Sahly HM; Baden LR; Essink B; Doblecki-Lewis S; Martin JM; Anderson EJ; Campbell TB; Clark J; Jackson LA; Fichtenbaum CJ; Zervos M; Rankin B; Eder F; Feldman G; Kennelly C; Han-Conrad L; Levin M; Neuzil KM; Corey L; Gilbert P; Janes H; Follmann D; Marovich M; Polakowski L; Mascola JR; Ledgerwood JE; Graham BS; August A; Clouting H; Deng W; Han S; Leav B; Manzo D; Pajon R; Schödel F; Tomassini JE; Zhou H; Miller J;
N Engl J Med; 2021 Nov; 385(19):1774-1785. PubMed ID: 34551225
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Baden LR; El Sahly HM; Essink B; Kotloff K; Frey S; Novak R; Diemert D; Spector SA; Rouphael N; Creech CB; McGettigan J; Khetan S; Segall N; Solis J; Brosz A; Fierro C; Schwartz H; Neuzil K; Corey L; Gilbert P; Janes H; Follmann D; Marovich M; Mascola J; Polakowski L; Ledgerwood J; Graham BS; Bennett H; Pajon R; Knightly C; Leav B; Deng W; Zhou H; Han S; Ivarsson M; Miller J; Zaks T;
N Engl J Med; 2021 Feb; 384(5):403-416. PubMed ID: 33378609
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Falsey AR; Sobieszczyk ME; Hirsch I; Sproule S; Robb ML; Corey L; Neuzil KM; Hahn W; Hunt J; Mulligan MJ; McEvoy C; DeJesus E; Hassman M; Little SJ; Pahud BA; Durbin A; Pickrell P; Daar ES; Bush L; Solis J; Carr QO; Oyedele T; Buchbinder S; Cowden J; Vargas SL; Guerreros Benavides A; Call R; Keefer MC; Kirkpatrick BD; Pullman J; Tong T; Brewinski Isaacs M; Benkeser D; Janes HE; Nason MC; Green JA; Kelly EJ; Maaske J; Mueller N; Shoemaker K; Takas T; Marshall RP; Pangalos MN; Villafana T; Gonzalez-Lopez A;
N Engl J Med; 2021 Dec; 385(25):2348-2360. PubMed ID: 34587382
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Anderson EJ; Rouphael NG; Widge AT; Jackson LA; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Corbett KS; Swanson PA; Padilla M; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Martinez DR; Baric R; Buchanan W; Luke CJ; Phadke VK; Rostad CA; Ledgerwood JE; Graham BS; Beigel JH;
N Engl J Med; 2020 Dec; 383(25):2427-2438. PubMed ID: 32991794
[TBL] [Abstract][Full Text] [Related]
10. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Sadoff J; Le Gars M; Shukarev G; Heerwegh D; Truyers C; de Groot AM; Stoop J; Tete S; Van Damme W; Leroux-Roels I; Berghmans PJ; Kimmel M; Van Damme P; de Hoon J; Smith W; Stephenson KE; De Rosa SC; Cohen KW; McElrath MJ; Cormier E; Scheper G; Barouch DH; Hendriks J; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H
N Engl J Med; 2021 May; 384(19):1824-1835. PubMed ID: 33440088
[TBL] [Abstract][Full Text] [Related]
11. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
12. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
14. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Lopez P; Bravo L; Buntinx E; Borja-Tabora C; Velasquez H; Rodriquez EJ; Rodriguez CA; Carlos J; Montellano MEB; Alberto ER; Salvani-Bautista M; Huang Y; Hu B; Li P; Han HH; Baccarini C; Smolenov I
Hum Vaccin Immunother; 2023 Dec; 19(1):2206359. PubMed ID: 37226504
[TBL] [Abstract][Full Text] [Related]
16. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
Jackson LA; Anderson EJ; Rouphael NG; Roberts PC; Makhene M; Coler RN; McCullough MP; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott A; Flach B; Doria-Rose NA; Corbett KS; Morabito KM; O'Dell S; Schmidt SD; Swanson PA; Padilla M; Mascola JR; Neuzil KM; Bennett H; Sun W; Peters E; Makowski M; Albert J; Cross K; Buchanan W; Pikaart-Tautges R; Ledgerwood JE; Graham BS; Beigel JH;
N Engl J Med; 2020 Nov; 383(20):1920-1931. PubMed ID: 32663912
[TBL] [Abstract][Full Text] [Related]
17. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
19. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
Chu L; McPhee R; Huang W; Bennett H; Pajon R; Nestorova B; Leav B;
Vaccine; 2021 May; 39(20):2791-2799. PubMed ID: 33707061
[TBL] [Abstract][Full Text] [Related]
20. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
